High Dose Bupropion for Smoking Cessation
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anhedonia
- Cessation, Tobacco
- Smoking (Tobacco) Addiction
- Smoking Cessation
- Smoking Tobacco
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants will be randomly assigned to receive either 300 or 450 mg of Bupropion XL.Masking: Triple (Participant, Care Provider, Outcomes Assessor)Masking Description: Participant will be unaware of which medication condition they have been assigned to, the care provider will not know which dose of medication they are distributing.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 65 years
- Gender
- Both males and females
Description
Participants will be randomly assigned to either receive 300 mg of BUP-XL or 450 mg of BUP-XL with an aim to quit smoking. They will take the medication for 8 weeks while simultaneously receiving counseling to set a quit date and stay motivated to quit. Medication will be administered for 4 weeks be...
Participants will be randomly assigned to either receive 300 mg of BUP-XL or 450 mg of BUP-XL with an aim to quit smoking. They will take the medication for 8 weeks while simultaneously receiving counseling to set a quit date and stay motivated to quit. Medication will be administered for 4 weeks before and 4 weeks after designated quit-date. Post-treatment follow-up appointment will be scheduled for 8, 16, and 26 weeks post treatment so assess commitment to quitting and overall success of the study.
Tracking Information
- NCT #
- NCT03326128
- Collaborators
- University of California, Los Angeles
- University of California, San Diego
- Investigators
- Principal Investigator: Adam M Leventhal, PhD University of Southern California
Get Well Soon